FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a composition for nicotinic immunonanotherapy containing synthetic nanocarriers having a polymeric surface conjugated with a variety of nicotine residues with the variety of the nicotinic residues on the nanocarrier form an immunogenic surface providing a low affinity, a high-avidity binding of the nicotinic residues to the surfaces of an antigen presenting cell (APC) compared with an antibody binding, and a pharmaceutically acceptable excipient. The invention provides the nanocarriers capable to stimulate an immune response in T-cells and/or B cells and to produce the antinicotin antibodies with the humoral and cellular response to be achieved in the absence of an exogenous adjuvant.
EFFECT: invention provides the absence of the non-specific response on an inflammation caused by an adjuvant.
17 cl, 37 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TARGETING OF ANTIGEN-PRESENTING CELLS OF IMMUNONANOTHERAPY DRUGS | 2009 |
|
RU2497542C2 |
| ADJUVANT ADDITION TO IMMUNONANOTHERAPEUTIC AGENTS | 2009 |
|
RU2496517C2 |
| EXOTOXIN A PSEUDOMONAS WITH LESS IMMUNOGENIC T-AND/OR B-CELL EPITHOPES | 2012 |
|
RU2627216C2 |
| COMPOSITIONS FOR T-CELL THERAPY WITH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2018 |
|
RU2819805C2 |
| HAPTEN-CARRIER CONJUGATES AND APPLICATION | 2003 |
|
RU2326693C2 |
| APPLICATION OF HEAT-SHOCK PROTEINS FOR IMPROVING EFFECTIVENESS OF ANTIBODY THERAPIES | 2003 |
|
RU2375077C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| PEPTOID LIGANDS FOR AUTOIMMUNE T-CELL RECOVERY AND PROCESSING | 2010 |
|
RU2563822C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2478400C2 |
| VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | 2010 |
|
RU2600798C2 |
